The subscription price for warrants series TO 1 in Ascelia Pharma has been determined to SEK 2.15 and the exercise period is initiated on 1 April 2025
In connection with the Rights Issue of units completed in September 2024, Ascelia Pharma issued a total of 20,773,992 warrants series TO 1. One (1) warrant series TO 1 entitles the holder to subscribe for one (1) new ordinary share in the Company. The exercise price for the warrants series TO 1 amounts to seventy (70) percent of the volume-weighted average price of the Company’s share on Nasdaq Stockholm during the period from and including 14 March 2025 up to and including 28 March 2025. During the measurement period, the volume-weighted average price in the Company’s share was approximately SEK 3.07, therefore, the exercise price for the warrants series TO 1 has been determined to SEK 2.15. The exercise period for the warrants series TO 1 runs during the period from and including 1 April 2025 up to and including 15 April 2025.
Summarized terms and timeline for the warrants:
- Last day of trading in warrants series TO 1: 11 April 2025.
- Exercise period of warrants series TO 1: 1 April 2025 – 15 April 2025.
- Exercise price: SEK 2.15 per share.
How warrants are exercised
Nominee-registered warrants (Custody account)
Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Directly registered warrants (Securities account)
No issue statement nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form (please find form in the link below). The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.
Summary of terms for Ascelia Pharma Warrants Series TO 1 exercise was presented in a press release.
Please find further information and forms for subscription for Directly registered warrants below.
Documents 2025